https://orcid.org/0000-0001-5559-3913
Abstract
Elevated dsDNA levels in ST-elevated myocardial infarction (STEMI) patients are associated with increased infarct size and worse clinical outcomes. However, the direct effect of dsDNA on platelet activation remains unclear. This study aims to investigate the direct influence of dsDNA on platelet activation, thrombosis, and the underlying mechanisms.
Analysis of clinical samples revealed elevated plasma dsDNA levels in STEMI patients, which positively correlated with platelet aggregation and markers of neutrophil extracellular traps such as MPO-DNA and CitH3. Platelet assays demonstrated the activation of the cGAS–STING pathway in platelets from STEMI patients. DsDNA directly potentiated platelet activation and thrombus formation. Mechanistic studies using G150 (cGAS inhibitor), H151 (STING inhibitor), and MCC950 (NLRP3 inhibitor), as well as cGAS−/−, STING−/−, and NLRP3−/− mice, showed that dsDNA activated cGAS, a previously unreported DNA sensor in platelets, and induced activation of the STING/NLRP3/caspase-1/IL-1β axis. This cascade enhanced platelet activation and thrombus formation. Platelet cGAS depletion or Palbociclib, a cGAS–STING inhibitor, approved by the FDA for advanced breast cancer, ameliorated myocardial ischaemia-reperfusion injury in ApoE−/− mice fed with a high-fat diet for 12 weeks.
These results suggested that dsDNA is a novel driver of platelet activation and thrombus formation in STEMI patients.
Following myocardial I/R injury, neutrophil activation results in the release of NETs containing a substantial amount of dsDNA. DsDNA directly enhances platelet activation and thrombotic potential via cGAS/STING/NLRP3/caspase-1/IL-1β signaling pathway, and aggravate myocardial infarction. Platelet cGAS depletion or cGAS-STING inhibitor could attenuate myocardial I/R injury.
